Kane Biotech Completes Enrollment in U.S. Case Series Studies of its revyve® Antimicrobial Wound Gel and Spray

Rhea-AI Summary

Kane Biotech (OTCQB:KNBIF) has successfully completed enrollment for its revyve® Antimicrobial Wound Gel and Spray U.S. Case Series Studies, surpassing its target with 28 participants versus the planned 25. The studies, involving wound care and burn specialists in the U.S., focus on the FDA 510(k) cleared revyve Antimicrobial Wound Gel.

The company plans to present the clinical data at various medical meetings throughout 2025 and 2026. According to Interim CEO Dr. Robert Huizinga, there has been encouraging interest from both clinicians and patients, with revyve products showing potential to significantly improve outcomes for patients with challenging wounds and burns.

Positive

• Exceeded enrollment target with 28 participants vs planned 25
• FDA 510(k) clearance already obtained for revyve Antimicrobial Wound Gel
• Strong interest from clinicians and patients in the U.S.

Negative

• Results from the case series are not yet available
• Data presentation timeline extends into 2026, indicating a lengthy evaluation process

WINNIPEG, Manitoba, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech” or “Kane”) today announces that it has enrolled 28 participants in its revyve^® Antimicrobial Wound Gel and Spray U.S. Case Series Studies, exceeding its 25-participant target.

US FDA 510(k) cleared revyve Antimicrobial Wound Gel

For the clinical series, Kane engaged wound care and burn specialists in the U.S. Data is anticipated to be presented at various medical meetings in 2025 and 2026.

“Interest from clinicians and patients in the U.S. case series is encouraging,” said Dr. Robert Huizinga, Interim CEO. “revyve products can meaningfully improve outcomes for those suffering from challenging wounds and burns.”

About Kane Biotech Inc. (TSX-V: KNE)

Kane Biotech is developing novel wound care treatments that disrupt biofilms and transform healing outcomes. Biofilms are one of the main contributors to antibiotic resistance in wounds which results in serious clinical outcomes and significant cost. revyve^® addresses both biofilms and wound bacteria. Its revyve^® Antimicrobial Wound Gel and revyve^® Antimicrobial Wound Gel Spray are US FDA 510(k) cleared. To learn more about revyve, visit revyvegel.com or revyvegel.ca.

Join Kane’s Distribution List & Social Media:

To stay informed on the latest developments, sign-up for the Company’s email distribution list HERE.

Follow Kane

Website: kanebiotech.com

LinkedIn: https://www.linkedin.com/company/kanebiotech/

For more information:

Dr. Robert Huizinga		Ray Dupuis
Interim CEO		Chief Financial Officer
Kane Biotech Inc.		Kane Biotech Inc.
rhuizinga@kanebiotech.com		rdupuis@kanebiotech.com
(780) 970-1100		(204) 298-2200

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Caution Regarding Forward-Looking Information
This press release contains certain statements regarding Kane Biotech Inc. that constitute forward-looking information under applicable securities law. These statements reflect management’s current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to, risks relating to the Company’s: (a) financial condition, including lack of significant revenues to date and reliance on equity and other financing; (b) business, including its early stage of development, government regulation, market acceptance for its products, rapid technological change and dependence on key personnel; (c) intellectual property including the ability of the Company to protect its intellectual property and dependence on its strategic partners; and (d) capital structure, including its lack of dividends on its common shares, volatility of the market price of its common shares and public company costs. Further information about these and other risks and uncertainties can be found in the disclosure documents filed by the Company with applicable securities regulatory authorities, available at www.sedar+.ca. The Company cautions that the foregoing list of factors that may affect future results is not exhaustive.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/29d77582-1218-4bbc-9c31-ebd8cec3ea69

FAQ

How many participants did Kane Biotech enroll in its revyve wound treatment case series?

Kane Biotech enrolled 28 participants in its revyve® Antimicrobial Wound Gel and Spray U.S. Case Series Studies, exceeding its original target of 25 participants.

What is the regulatory status of Kane Biotech's revyve Antimicrobial Wound Gel?

The revyve Antimicrobial Wound Gel has received FDA 510(k) clearance for use in the United States.

When will Kane Biotech (KNBIF) present the results of its revyve case series?

Kane Biotech plans to present the clinical data at various medical meetings throughout 2025 and 2026.

What conditions does Kane Biotech's revyve product target?

The revyve products are designed to treat challenging wounds and burns, with the potential to meaningfully improve patient outcomes.

Who is leading Kane Biotech's revyve clinical studies?

The studies are being conducted under the leadership of Dr. Robert Huizinga, Kane Biotech's Interim CEO, with participation from wound care and burn specialists in the U.S.